Isotechnika's partner Lux to appeal EMA CHMP decision against Luveniq
Links shared publicly online about this topic.
- 195total visits
Isotechnika's partner Lux to appeal EMA CHMP decision against Luveniq
Isotechnika Pharma Inc. today announced that its partner, Lux Biosciences, Inc. will appeal the European Medicines Agency's (EMA) decision not to approve Luveniq™ (voclosporin) as a treatment for noninfectious uveitis involving the intermediate or posterior segments of the eye.
View full resource at news-medical.net
Most Recently Shared on June 24, 2011 at 5:19 pm By:
Isotechnika's partner Lux to appeal EMA CHMP decision against Luveniq: Isotechnika Pharma Inc. today announced t... http://bit.ly/jEZHbZ
Advertisement
